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Abstract
Aβ-amyloid deposition is a key feature of Alzheimer’s disease, but Consortium to Establish a Registry for Alzheimer's
Disease (CERAD) assessment, based on neuritic plaque density, shows a limited relationships to dementia. Thal
phase is based on a neuroanatomical hierarchy of Aβ-deposition, and in combination with Braak neurofibrillary
tangle staging also allows derivation of primary age-related tauopathy (PART). We sought to determine whether
Thal Aβ phase predicts dementia better than CERAD
in a population-representative cohort (n = 186) derived from the Cognitive Function and Ageing Study (CFAS).
Cerebral amyloid angiopathy (CAA) was quantitied as the number of neuroanatomical areas involved and cases
meeting criteria for PART were defined to determine if they are a distinct pathological group within the ageing
population. Agreement with the Thal scheme was excellent. In univariate analysis Thal phase performed less well as
a predictor of dementia than CERAD, Braak or CAA. Logistic regression, decision tree and linear discriminant analysis
were performed for multivariable analysis, with similar results. Thal phase did not provide a better explanation of
dementia than CERAD, and there was no additional benefit to including more than one assessment of Aβ in the
model. Number of areas involved by CAA was highly correlated with assessment based on a severity score (p <
0.001). The presence of capillary involvement (CAA type I) was associated with higher Thal phase and Braak stage
(p < 0.001). CAA was not associated with microinfarcts (p = 0.1). Cases satisfying pathological criteria for PART were
present at a frequency of 10.2% but were not older and did not have a higher likelihood of dementia than a
comparison group of individuals with similar Braak stage but with more Aβ. They also did not have higher
hippocampal-tau stage, although PART was weakly associated with increased presence of thorn-shaped astrocytes
(p = 0.048), suggesting common age-related mechanisms. Thal phase is highly applicable in a population-
representative setting and allows definition of pathological subgroups, such as PART. Thal phase, plaque density,
and extent and type of CAA measure different aspects of Aβ pathology, but addition of more than one Aβ measure
does not improve dementia prediction, probably because these variables are highly correlated. Machine learning
predictions reveal the importance of combining neuropathological measurements for the assessment of dementia.
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Introduction
Aβ amyloid deposition is widely accepted for decades as
central to AD pathology, based on the amyloid cascade hy-
pothesis as an upstream event [39]. However, population-
based studies, including the United Kingdom-
based Cognitive Function and Ageing Study (CFAS) have
shown a limited relationship between histological Aβ plaque
deposition and dementia status due to overlap in Aβ burden
between demented and non-demented individuals, particu-
larly in the oldest old [27, 33, 37].
Traditional assessment of cerebral Aβ load according
to the Consortium to Establish a Registry for Alzhei-
mer’s Disease (CERAD) standardised neuropathology
protocol, proposed nearly 30 years ago, is based on
plaque density, particularly neuritic plaques, in cortical
areas [29]. Additional neuropathological measures have
been proposed to assess Aβ. Thal phase provides a more
finely graded assessment of Aβ-deposition, based on a
proposed hierarchical progression of Aβ through neuro-
anatomical areas [42], analogous to the “Braak” method
for assessment of neurofibrillary tangles (NFT) [7]. Thal
phase, based on the detection of immunopositive amyl-
oid in cortical and subcortical areas, distinguishes 5
phases based on progressive deposition of amyloid in
neocortex (1), allocortex / limbic (2), diencephalon/basal
ganglia (3), brainstem/midbrain (4), cerebellum (5). The
assessment does not distinguish between compact/fibril-
lary and diffuse amyloid deposits. Thal phase, combined
with CERAD neuritic plaque score and Braak NFT
staging are incorporated into current National Institute
on Aging recommendations for neuropathological as-
sessment of dementia cases to derive the ABC score
[31]. BrainNet Europe validated Thal phase and showed
it can be applied consistently across European centres
and assessors [1]. The Thal scheme also includes a quali-
tative assessment of the presence of cerebral amyloid
angiopathy (CAA) in leptomeningeal and cortical vessels.
CAA type 1 implies capillary amyloid is present, with or
without staining in larger vessels. In CAA type 2 capil-
lary amyloid is at most a minor component [42].
Integration of Thal Aβ and Braak NFT staging identi-
fied a putative sub-group of cases with mesial temporal
tau pathology, up to Braak NFT stage IV, and little Aβ
pathology, designated as “Primary age-related tauopathy
(PART)”. Those cases having up to Braak stage IV but
no Aβ pathology (Thal stage 0) are designated PART-
definite and those or with mild Aβ pathology (Thal
stages I-II) are designated PART-possible [10]. Whilst
these distinctions can be pathologically defined and
staged, debate remains as to whether PART is a distinct
age-related entity or forms part of the Alzheimer path-
ology spectrum [11]. PART is associated with older age
at death and lower cognitive scores [10], but its relation-
ship to dementia and its natural history in unselected
elderly populations is uncertain. Tau pathology may also
occur in astrocytes in the ageing brain, particularly in
mesial temporal structures [22, 38]. This includes vari-
ous morphologies, including thorn-shaped astrocytes
and granular or fuzzy astrocytes, and appears to be pre-
dominantly 4R tau. The assessment of this age-related
tauopathy has recently been harmonized into the entity
of aging-related tau astrogliopathy (ARTAG) [18, 19],
though its relationship to other older age pathologies re-
mains to be fully defined.
We aimed to investigate the variability of Aβ pathology
in a population-representative neuropathology cohort and
the relationship of Aβ-derived staging measures to
dementia. We investigated the validity of Thal phase in a
population-based cohort, hypothesising that inclusion of
Thal Aβ phase would better predict dementia compared
with CERAD score and improve pathological models of
dementia. We explored quantitative assessment of CAA
and determined whether cases meeting criteria for PART
are a distinct pathological group within the ageing
population.
We explored whether newer neuropathological mea-
sures improve the performance of Aβ measures for
prediction of dementia. Specifically, we sought to: i. de-
termine the validity of Thal phase in a population-
representative cohort; ii. conduct statistical modelling
and machine learning prediction to test whether inclu-
sion of Thal Aβ phase offers better dementia prediction
than CERAD score; iii. Provide quantitative assessment
of CAA and determine its relationship to parenchymal
Aβ and dementia; iv. identify cases meeting criteria for
PART to determine whether they can be separated as a
distinct pathological grouping within the ageing popula-
tion and to determine the relationship to ARTAG.
Methods
Cohort
Tissue was used from the Newcastle and Cambridge centre
sub-cohorts of CFAS (n = 186), as in our previous study
[45]. Use of complete CFAS sub-cohorts maintains the
population-representative nature of the study, without case
pre-selection. Neuropathological lesions, including CERAD
plaque score, Braak NFT, BrainNet Neuropil thread stage,
ARTAG, vascular pathology and the presence of microin-
farct stage were also previously assessed [16, 27, 33, 44, 45].
Hippocampal tau NFT stage, based on the method of Lace
et al., was available on 94 cases from the Cambridge cohort
[23]. Dementia status at death was established as present,
absent, or uncertain, on the basis of AGECAT algorithm,
death certification and Retrospective Informant Interview
(RINI) [26, 32, 37, 44]. The study was undertaken with eth-
ical approval from a UK Multicentre Research Ethics Com-
mittee (10/H0304/61).
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Neuropathological methods
Immunohistochemical detection of Aβ in formalin-fixed,
paraffin-embedded sections (5 μm) used a standard
avidin-biotin complex (ABC) method. Sections were
deparaffinised, rehydrated to water and endogenous per-
oxidase activity quenched by placing the sections in 0.3%
H2O2/methanol for 20min at room temperature (RT).
After antigen retrieval (0.01M tri-sodium citrate pH 6.5,
microwave 10min) sections were subjected to formic acid
pre-treatment for 60min at RT. Following incubation with
1.5% normal serum for 30min at RT, the sections were in-
cubated with anti-Aβ (Clone 6F/3D; DakoCytomation,
UK) at the optimal antibody dilution of 1:200 for 60min
at RT. To visualise antibody binding, the horse-radish per-
oxidase avidin biotin complex was used (Vectastain Elite
kit, Vector Laboratories, UK) with 3,3′-diaminodenzidine
(DAB) as the chromagen (Vector Laboratories, UK;
brown) and lightly counterstained with Mayer’s haema-
toxylin. Negative controls, either omission of the primary
antibody or isotype controls, were included in every run.
Assessment of Aβ phase was performed according to
the Thal scheme, and BrainNet Europe approach [1, 42],
based on the assessment of parenchymal deposits in:
frontal, temporal, parietal and occipital cortex, temporal
cortex adjacent to hippocampus (phase 1); hippocampus
and cingulate gyrus (phase 2); striatum and basal
forebrain (phase 3), midbrain central grey matter and
substantia nigra (phase 4); cerebellum (phase 5). For
many of the cases used in this study, basal forebrain was
not well represented so that assessment of phase 3 was
essentially dependent on striatal Aβ-deposition. Cyto-
plasmic Aβ was discounted for assessment of phase.
Neurofibrillary tangles were assessed by Braak stage [6].
Plaques were assessed using the CERAD method [29],
and for modelling, the maximum cortical neuritic plaque
score was used.
We modified assessment of CAA to provide finer detail
of the severity of CAA deposition. In addition to recording
type I and II as in the scheme [42], we used two measures
to further refine assessment of the burden of CAA: i. The
number of anatomical areas involved from all the areas in
the sampling set to obtain a measure of extent (number of
areas out of 9 maximum); ii. The severity of leptomenin-
geal and parenchymal vascular amyloid in four neocortical
areas according to the method of Love et al.: (score 1 -
segmental involvement of vessels; score 2 - circumferential
involvement; score 3 - widespread circumferential involve-
ment, separately for parenchymal and leptomeningeal ves-
sels [25]). Scores for leptomeningeal and parenchymal
amyloid were summed in the four areas, giving a severity
score out of maximum of 24.
Definite PART was defined as Aβ stage 0/Braak NFT
stage I-IV and possible PART as Aβ stage 1–2/Braak
NFT stage I-IV [10].
Statistical analysis
Statistical analyses were performed using IBM SPSS v24
and RStudio v1.14. The Kolmogorov-Smirnov test was
used to assess variables for a normal distribution. Differ-
ences in scores between 2 groups were assessed by
Mann Whitney for unpaired data, and Wilcoxon signed
ranks for related data. Correlation analysis used Spear-
man’s rho (ρ). Comparisons between multiple groups,
with related data, were made using Friedman’s ANOVA
for non-parametric data. Chi-square was used for cat-
egorical comparisons. Interactions between age, Thal
and Braak stages were assessed using ANOVA.
For group comparisons, Braak NFT stages were divided
into entorhinal (0-II), limbic (III-IV) and isocortical stages
(V-VI). PART-definite (PART-d) cases were defined as
those without amyloid and with Braak NFT stage I-IV.
Part-possible (PART-p) cases were defined as Braak NFT
stages I-IV and Thal phases 1–2 [10]. To compare PART
with cases showing greater Aβ-pathology that may be
more typical of AD-neuropathology progression, a PART-
comparison group was defined with Braak NFT stages I-
IV, but with Thal phases 3–5 (designated PART-c). See
Fig. 5a for representation of these groups. For age groups,
cases were divided into those individuals who were 79 yrs.
or less at death (n = 39), a middle group of 80-89 yrs. (n =
83), and the oldest group, 90 yrs. and above (n = 63). Dif-
ferences between age as a continuous variable and PART
classes was assessed using the Wilcoxon test. All tests
were two-tailed and significance was set at p < 0.05 except
that, in cases where we compared all five neuropatho-
logical features, an alpha threshold for significance of 0.01
for significance after Bonferroni correction was used.
All cases were included for assessment of relationships
between pathological variables, but cases where demen-
tia was uncertain (i.e. could not be established from our
algorithmic approach) were excluded from analyses in
relation to dementia status.
Predictive modelling using neuropathological features
In order to measure the ability of each classifier to gen-
eralise to some independent set, the out of bootstrap
method was used. Samples were partitioned into a
training set (75% of samples) and a validation set (25%
of samples). The classifier was then trained on the
training set, and performance evaluated on the valid-
ation set. This process was repeated by resampling the
patients 1000 times with replacement to generate mul-
tiple test sets. The mean and standard deviation of the
classification accuracy based on the predicted and ob-
served clinical dementia diagnosis were computed for
each sample. Data from CFAS was cleaned using
pandas with certain factors, such as age groups being
one hot encoded. Next we applied three different yet
classical machine learning approaches for predicting
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dementia; logistic regression, decision tree and linear
discriminant analysis (LDA) [12, 30, 46].
Logistic regression parameterises a sigmoid function
to separate two classes of data. In this paper, the two
classes were people with dementia and those without,
with an odds ratio for a risk factor estimated. Logistic
regression estimates the probability of having one of the
two outcomes, is often used for this type of classification
and it is relatively interpretable, not very computation-
ally intense and very common. The logistic regression
classifier was implemented using sklearn.linear_model
package in the Python scikit-learn library.
Decision trees can be visualised as a flow chart or a
tree structure where a node in a tree represents some
feature and a branch is representative of a decision rule.
The white box nature of decision trees makes them par-
ticularly well suited to applications where the under-
standing of the working of the classifier are essential. In
addition to this, they are well suited to high dimensional
data and, unlike the logistic regression model, are non-
parametric. The decision tree class from the sklearn.tree
package was used to implement the decision tree.
Linear discriminant analysis models the distribution
of the risk factors separately in each dementia class,
and then it uses Bayes theorem to estimate the prob-
ability of a linear combination of features from the
risk factors being representative of a dementia class.
One advantage of linear discriminant analysis over lo-
gistic regression is that it is more stable for smaller
data sets and parameters estimates tend to be more
stable for classes that are more distinctly separated.
LDA has the assumption of normality in the inde-
pendent variables. The Kolmogorov-Smirnov (KS) test
was used to assess normality for these variables. The
classifier was implemented using the LDA class from
sklearn.discriminant_analysis.
Results
Characteristics of studied sample
The study cohort included 186 individuals from the
Cambridge (n = 117) and Newcastle (n = 69) centres
(age range 74 to 93 years at death). The demographics
of the cohort are shown in Table 1. Dementia at
death was present in 58% (107) of individuals and
38% (70) did not have dementia. Dementia status was
uncertain for 9 individuals.
Thal phase distribution across the cohort
The Newcastle and Cambridge subcohorts showed a
similar distribution of Thal Aβ phases. Both had me-
dian scores of 3, with no significant difference in
scores between centres (Mann Whitney p = 0.257).
Agreement with the Thal scheme was excellent. Only
2 individuals deviated from the scheme; both had
Thal phase 5 pathology in which staining in the stage
4 (midbrain) areas was not observed. More of the
brains had pathology distributed towards the higher
Thal phases, particularly for age groups 80-89 yrs. and
90 yrs. and above (Fig. 1a). CERAD plaque score,
Braak NFT stage or CAA were not skewed towards
higher scores at older ages (Fig. 1c-d).
CAA
CAA in any area was present in 75.3%. Of respondents
with CAA (n = 140), 48.6% (68) were CAA type I
(Fig. 2a,b), and 51.4% (72) were type II. CAA was scored
as present or absent in the 10 assessed anatomical areas.
The distribution of the number of areas involved by
CAA was positively skewed with more individuals having
a lower score and a score of 0 being the most prevalent
(Fig. 2c). This was so for all age groups (Fig. 1d). CAA
was most frequently detected in occipital cortex (66% of
individuals in the cohort) compared to frontal cortex
(55%), temporal cortex (53%) and parietal cortex (53%).
Semi-quantitative severity of CAA involvement, assessed
in parenchyma and leptomeningeal vessels in four neocor-
tical areas [25] was higher in the leptomeninges than in
parenchyma (Wilcoxon signed ranks p < 0.001). There
was strong correlation between the number of areas with
CAA and severity of CAA as measured by the sum of the
scores of vascular involvement in parenchymal and lepto-
meningeal vessels (Spearman’s p < 0.001, rs = 0.94), indi-
cating that either measure could be used as a global-brain
semi-quantitative measure of CAA. Therefore, in further
analyses we used only the number of areas with CAA.
The number of areas with CAA correlated with both
Thal Aβ phase (Spearman’s p < 0.001, rs = 0.64) and
Braak NFT stage (p < 0.001, rs = 0.52). Thal phase
Table 1 Demographic and cognitive profile according to clinical dementia status
No Dementia (n = 70) Dementia (n = 107) Unknown (n = 9)
Womena 37 (53%) 72 (67%) 4 (44%)
Age at death (years)b 84 (76–89) 89 (84–93) 84 (74–87)
Years since last cognitive assessmentb 6 (3–10) 6 (3–10) 11 (5–14)
MMSE at last assessment b 25 (21–24) 20 (17–24) 25 (24–25)
a n (%)
b median (inter-quartile range)
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Fig. 1 Histogram showing distribution of Aβ and tau pathology across the cohort subdivided into 3 age groups (n = 186), showing that older
age groups show a shift to higher Thal phases; this is less apparent with other measures. a Thal phase, b CERAD neuritic plaque score, c Braak
neurofibrillary tangle stage, d number of areas with CAA
Fig. 2 Cerebral amyloid angiopathy scores are positively skewed in the population, most individuals having a low score, and CAA type 1 is
associated with high Braak stage and Thal phase. a and b Aβ deposition in occipital cortex showing deposition in leptomeningeal and
parenchymal vessels, including capillaries (type I CAA). c Histogram showing distribution of CAA number of areas score. d Boxplots of Braak and
Thal stages for cases with no CAA or with CAA types I and 2
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differed by CAA, absent, type I and type II CAA
(Kruskal Wallis p < 0.001), as did Braak stage (p < 0.001).
For both Thal and Braak, higher scores were associated
with CAA type I (Fig. 2d).
We next determined whether CAA was associated with
cortical microinfarcts. The number of areas with CAA did
not correlate with the number of areas with cortical
microinfarcts (Spearman’s p = 0.1, rs = 0.12), with subcor-
tical lacunes (p = 0.29, rs = − 0.08) or the total number of
areas with microinfarcts (p = 0.42, rs = 0.06). There were
no associations between CAA and microinfarcts in frontal
(Chi Square χ2 = 0.94 1df, p = 0.33), temporal (χ2 = 0.34
1df, p = 0.56), parietal (χ2 = 0.19 1df, p = 0.67) or occipital
(χ2 = 0.76 1df, p = 0.39) cortex.
Relationships of Aβ deposition to dementia
We next investigated how Thal Aβ phase related to de-
mentia. Thal phase measures neuroanatomical progres-
sion of Aβ rather than severity in only the neocortical
areas and has a more granular scale. We hypothesised
that Thal phase would better relate to dementia than
CERAD plaque score, and provide additional informa-
tion. The proportion of individuals with dementia
increased with increasing Thal phase but this was also
seen with plaque score and Braak NFT stage. The likeli-
hood of dementia also increased in individuals with high
CAA scores (Fig. 3). Importantly, cases of dementia were
present in respondents with low burdens of Aβ, either
by Thal or CERAD, and in those with low Braak NFT
stage. The likelihood of dementia increased steadily with
increasing Thal phase and Braak stage, except between
stages 2 and 3. For both Thal and Braak, there were age-
dependent relationships to dementia such that, for a
given burden of pathology, individuals with dementia
tended to be older those without (ANOVA p < 1.30e-06;
Fig. 4), consistent with the role of age as a risk factor for
dementia. However, there were low correlations between
age and Thal phase and Braak stage for individuals with
or without dementia (Spearman’s rs < 0.37).
Accuracy of the prediction of dementia by these
neuropathological measures was assessed in univariate
analysis using logistic regression (Table 2). As univariate
predictors of dementia, plaque score, measures of CAA
and Braak stage all performed slightly better than Thal
phase; however, prediction accuracy could be much bet-
ter when using a combination of factors.
Fig. 3 Number of individuals with and without dementia showing increasing proportions of individuals with increasing scores for the four
pathological measures; a Thal phase, b Braak stage, c Number of areas with CAA, d neuritic plaque score. Red lines show likelihood of dementia
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Thal phase compared to plaque score in multivariable
prediction models
We then assessed the predictive value of Thal phase for
dementia in comparison with other measures when
combined with other factors. Logistic regression provide
similar results to two machine learning approaches, deci-
sion tree and LDA. The model was constructed using
the following variables: Age and brain weight; Thal
phase; Plaque score; Braak stage; CAA score. The model
gave predictive accuracy for dementia of 0.6773 (CI
0.674–0.6806) using logistic regression, 0.701 (0.6967–
0.7053) for decision tree and 0.6834 (0.6799–0.6869) for
LDA. When each parameter was dropped singly from
the model, age and brain weight had the largest effect.
The neuropathological parameters each had similar ef-
fects (Table 3). The effects of Thal compared to other
Aβ measures was assessed further by comparing Thal
phase, CERAD score or CAA score when singly added
to a model comprising age, brain weight and Braak score
(Table 4). Adding any of these Aβ-related parameters
gave a similar prediction performance compared to the
best performing multivariable model (Accuracy = 0.7026,
+/− 0.0048). This observation was consistent for the
three types of predictive algorithms used.
The relationship of Thal phase to Braak stage, and
characteristics of PART in the cohort
Thal Aβ phase correlated with Braak NFT stage (Spear-
man’s p < 0.001, rs = 0.63). We identified 19 PART-
definite cases (10.2%; Thal phase 0 / Braak NFT stage
I-IV) and 39 PART-possible cases (21%; Thal phases 1–
2 / Braak NFT stages I-IV), combined as 58 (31.2%)
PART-all cases (Fig. 5).
To further define the nature of cases satisfying PART
criteria in a population setting, we compared PART-
definite (PART-d) and PART-all (PART-a) groups to
those with the same Braak NFT stages (I-IV), but with
the higher burdens of Aβ-deposition that might be more
expected for typical AD neuropathological progression
(PART-c) to determine whether PART cases show dis-
tinct features from cases with greater amyloid burden.
We hypothesised that the oldest individuals may de-
velop mesial temporal tau formation with little amyloid.
However, neither PART-d nor PART-a groups were
older that the PART-c group (Wilcoxon test p > 0.67;
Fig. 5c). PART-d showed a lower likelihood of dementia
to the PART-c group, possibly due to the absence of as-
sociated Aβ, by definition, in PART-d. Both PART-d
and PART-c group control groups showed that individ-
uals with dementia tended to be older (Wilcoxon test
p < 0.01; Fig. 5d).
We then investigated whether PART cases have
more CAA compared to low Braak non-PART cases,
because of greater clearance of Aβ into vessels. How-
ever, this was not the case; the number of anatomical
areas with CAA was higher in the PART-c group
than in either PART-d (Wilcoxon rank sum p <
0.001) or PART-a (p < 0.001).
Fig. 4 Age distribution for individuals with and without dementia for each neuropathological stage showing that individuals with dementia tend
to older than those without for each Thal phase (a) and Braak stage (b)
Table 2 Univariate classifier (logistic regression) of dementia
status with different neuropathological features. The cross-
validated mean accuracy and error was computed. Plaque score,
measures of CAA and Braak stage all performed slightly better
than Thal phase as dementia predictors
Features of univariate classifier Mean accuracy (+/− error)
Thal Phase 0.5957 (+/− 0.0040)
Plaque score 0.6166 (+/− 0.0048)
CAA Type 0.6243 (+/− 0.0046)
CAA Areas 0.6222 (+/− 0.0047)
Braak Stage 0.6179 (+/− 0.0051)
Age (One hot encoded) 0.6540 (+/− 0.0038)
Brain weight 0.5721 (+/− 0.0032)
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We next investigated whether PART is associated with
ARTAG, another age-related tauopathy characterised by
various forms of glial tau, most commonly thorn-shaped
astrocytes (TSA) [18]. If PART is an age-related tauopa-
thy, a relationship to TSA might be expected. 63% of
PART-d cases had TSA compared to 38% of PART-c
(Chi Square χ2 = 3.98 1df p = 0.046). PART-a cases did
not show greater TSA than the PART-c group (χ2 = 0.47
1df p = 0.49). The number of areas with TSA was greater
in PART-d compared to the PART-c group (Mann
Whitney p = 0.048), but there was no difference between
the PART-a and PART-c groups (p = 0.43).
We hypothesised that, if PART represents a specific
mesial temporal tauopathy PART cases would show
more severe mesial temporal tau pathology than the
PART-c group. We therefore determined whether PART
cases had more hippocampal tau in a subcohort for
which we had previously staged hippocampal tau (n =
93) [23]. PART-d (Mann Whitney p = 0.35) did not
show a higher hippocampal tau load than the PART-c
group. PART-a showed a significant difference in hippo-
campal tau stage to the PART-c (p = 0.014); however,
contrary to our hypothesis the hippocampal stage was
lower in the PART-a group so that PART is not associ-
ated with higher levels of hippocampal tau.
Discussion
Main study findings
Staging of Aβ based on neuroanatomical progression of-
fers an alternative approach to semi-quantitative assess-
ment of Aβ plaques, and comparison with neurofibrillary
tangle staging allows further definition of the relative
variation in Aβ and tau pathology between individuals. In
this study, we show that Thal phase assessment is applic-
able to the continuum of amyloid burden found within a
population-derived cohort. Logistic regression and ma-
chine learning approaches gave similar results for multi-
variable analysis to show that Thal phase does not provide
a better explanation of dementia than the CERAD score.
Assessment of CAA based on the number of anatomical
areas involved, correlates with assessment of CAA based
on severity, whilst the presence of capillary involvement
(CAA type I) is associated with higher burdens of paren-
chymal Aβ and tau pathology. Thal phase allows ascer-
tainment of PART cases within the cohort with a
frequency of about 10% (for PART-d). Individuals with
PART reflect population variation in pathology, rather
than a discrete group within the population. PART
individuals were not older than the comparison group of
individuals with higher Aβ for the same Braak stages
(PART-c; Braak I-IV/Thal 3–5), although PART was asso-
ciated with ARTAG, suggesting a relationship with age-
related mechanisms. PART cases also did not show a
higher likelihood of dementia at death, although both
PART and the PART-c with dementia at death were older
than individuals without dementia.
Study limitations
There are a number of limitations to this study. The
study is focused on the variation and comparison of dif-
ferent measures of Aβ-deposition in a population-
derived sampled. This study does not include a compre-
hensive analysis of the various pathologies, such as α-
synuclein, TDP-43 and vascular pathology, that may
Table 3 Classification of dementia status with different algorithms and different combinations of neuropathology features.
Prediction accuracy and standard error are listed for each feature when it is omitted from the multivariable classifier. Age and brain
weight had the largest effect when dropped from the model, whilst the neuropathological parameters each had similar effects
Classifier Type Age & Brain weight Thal Phase Plaque score Braak Stage CAA No features omitted
Logistic Regression 0.6327 (+/− 0.0035) 0.6774 (+/− 0.0033) 0.6773 (+/− 0.0033) 0.6776
(+/− 0.0033)
0.6785 (+/− 0.0034) 0.6773 (+/− 0.0033)
Decision Tree 0.6327 (+/− 0.0040 0.6997 (+/− 0.0045 0.6929 (+/− 0.0045 0.7026
(+/− 0.0048
0.7011 (+/− 0.0047 0.7010 (+/− 0.0043)
LDA 0.6344 (+/− 0.0032) 0.6763 (+/− 0.0035) 0.6709 (+/− 0.0034) 0.6738 (+/− 0.0034) 0.6760
(+/− 0.0.0036)
0.6834 (+/− 0.0035)
Table 4 Comparison of CAA, Thal phase and plaque score importance in classifiers that also use age, brain weight and Braak stage.
Adding any one of the three Aβ-related parameters gave a similar prediction performance compared to the best performing
multivariable model. Accuracy and confidence intervals are listed for dementia prediction when each neuropathology feature is
omitted
Classifier (including age, brain weight and Braak score) CAA Thal Phase Plaque score
Logistic regression 0.6756 (+/− 0.0032) 0.6885 (+/− 0.0036) 0.6741 (+/− 0.0030)
Decision Tree 0.6798 (+/− 0.0042) 0.6940 (+/− 0.0043) 0.6980 (+/− 0.0044)
LDA 0.6705 (+/− 0.0033) 0.6748 (+/− 0.0034) 0.6737 (+/− 0.0034)
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coexist in the ageing brain, which may affect the
behaviour of Aβ-derived measures in modelling. Although
based on a well-characterised population-representative co-
hort that was not pre-selected for clinical diagnosis [8, 44],
the sample used for this study was limited to 186 partici-
pants. Using the Cambridge and Newcastle centre sub-
cohorts maintained the population-representative basis of
the study. The assessment of cognitive status was based on
the presence or absence of dementia at death [8, 37, 44].
The approach taken in CFAS is reliable for dementia as-
sessment in the population context, but the study did not
assess the relationship to mild cognitive impairment or to
atypical dementia syndromes. The study was focused on
the Aβ-deposition detectable by conventional immunohis-
tochemistry in formalin-fixed, paraffin embedded tissue. It
did not assess lower molecular weight soluble aggregates,
which may also relate to dementia [17, 28, 39], so that it
gives an incomplete view of the role of Aβ in dementia.
However, the approach used is appropriate for the study
aims of assessing morphology-based staging of Aβ, which
are currently the basis for complete clinicopathological
diagnosis. Incorporating measures of additional Aβ species
would be a valuable further step. This study did not assess
APOE genotype or tau haplotype, which may vary with AD
and tangle-predominant dementia [36]. The study, based
on autopsy samples is cross-sectional and assessment of
dementia necessarily retrospective. Longitudinal imaging
studies of cerebral Aβ suggested that its accumulation is
early in relation to cognitive decline, and may predict pro-
gression, whereas further cognitive decline is less related to
Aβ burden [43]. Our study could not detect such
interactions.
Thal phase and dementia
Thal phase [42], like Braak stage for NFT [7], is based on
the concept of progressive, hierarchical recruitment of
brain areas. The Thal scheme showed excellent validation
of this approach at the population level in this cohort. The
scheme is easy to apply and offers a more finely granular
Aβ assessment than the CERAD score [29].
In univariate analysis, however, Thal phase was less
predictive for dementia than CERAD and multivariable
analysis showed no advantage for Thal phase compared
to CERAD score, and its inclusion did not improve the
model when CERAD score was already included. Both
the logistic regression and machine learning approaches
gave similar results. This supports findings in other
studies. Serrano-Pozo et al., in 192 subjects in the longi-
tudinal cohort from the Alzheimer’s Disease Centers,
found that Thal phase did not significantly associate
with Clinical Dementia Rating Sum of Boxes (CDR-
SOB) or Mini-Mental State Examination scores and did
Fig. 5 a Schematic showing NFT vs Aβ progression, with a main sequence of cases showing co-progression of the two AD neuropathologies.
Cases can be defined showing NFT (Braak I-V) but no Aβ pathology corresponding to PART-d (red box), or with low levels of Aβ corresponding
to PART-p (pink box). A comparison group, designated PART-c with similar Braak stage but more Aβ (Braak I-IV/Thal 3.-5) can be defined as those
with more expected levels of Aβ for typical AD neuropathological progression (blue box). b likelihood of dementia for PART definite and
probable cases and for the comparison PART-c group. c Overall age distribution of PART groups. d Age distribution according to dementia status
for each of the PART groups
Wharton et al. Acta Neuropathologica Communications           (2019) 7:198 Page 9 of 12
not improve prediction of dementia, whereas CERAD
did associate with CDR-SOB [40]. Boluda et al. found a
lack of correlation between CERAD and Thal phase,
except at higher scores, but found that Thal phase was
more predictive of dementia than CERAD, although this
study used AD cases and controls and so may not have
reflected the continuum of pathology seen in a popula-
tion [4]. Braak NFT stage correlates with measures of
clinical course in AD, including final MMSE score, but
Thal phase does not after accounting for Braak [34]. The
CERAD method, whilst confined to the neocortex,
assesses neuritic plaques so that it may be detecting
more functionally significant Aβ-deposition compared to
inclusion of diffuse deposits using Thal phase. Thal
phase and CERAD score reflect different aspects of Aβ
as supported by the relationship of age with higher Thal
phases but not CERAD score, so that the increasing
neuroanatomical spread of diffuse Aβ is more related to
ageing. While Thal phase is related to the likelihood of
dementia, it does not improve prediction of dementia
compared to CERAD score in the diagnostic assessment
of cases. Including Thal phase, however, allows assess-
ment of variation in relative abundance of Aβ to tau and
the definition of subgroups such as PART cases.
Thal phase is highly correlated with Braak NFT stage,
although the anatomical hierarchies differ. For example,
Thal phase 1 reflects neocortical involvement by Aβ as the
earliest stage, whereas NFT formation shows earliest in-
volvement of entorhinal and hippocampal structures, and
the neocortex is involved at later stages [6, 7]. Some
authors suggest that tau pathology begins in brainstem
nuclei, although not all studies agree [3, 41]. Both the Thal
and Braak schemes are operationalised in the context
of a continuum of the respective pathologies. However
whilst Aβ and NFT tend to progress together, the differing
neuroanatomical hierarchies remain unexplained by
current theories of the amyloid cascade hypothesis.
Age and brain weight had a larger effect in the multi-
variable model than any of the individual neuropatho-
logical parameters as previously reported by CFAS [27]
and, for most of the individual Thal phases and Braak
stages, individuals with dementia were older than those
without. This was also true for each of the PART (−d
and –p) groups and the PART-c, comparison, group.
Age is the largest risk factor for dementia and ageing it-
self may impair cells through multiple mechanisms [24].
This supports the concept of aging mechanisms as add-
itional contributors to dementia and the importance of
age as a parameter in models of late-life dementia. .
CAA
CAA was present in around 75% of cases, and of those
with CAA approximately half were type I CAA, in which
there is also capillary involvement. This prevalence is
higher than in some studies. CAA prevalence has been
reported at 53.8% in an unselected autopsy series [21]
and 44.1% in the Honolulu-Asia Aging Study (HAAS), a
population representative study of male Japanese mi-
grants to Hawaii [35]. The prevalence estimate reported
here is more similar to a combined community-based
sample of 1113 individuals in the Rush Memory and
Aging Study and the Religious Orders Study (78.9%) [5].
As in previous studies [21, 35], the highest regional in-
volvement by CAA is in the occipital cortex.
We found that quantifying the number of areas with
CAA correlated well with assessments of CAA severity
based on extent of vascular involvement in neocortical
areas [25], and so used this in our analyses. CAA
correlated with Thal phase. As in previous studies, the
presence of CAA was associated with greater burdens
of amyloid and tau with a stronger association with
Aβ [2, 5, 13, 21, 35], and capillary involvement (CAA type
1) was associated with higher levels of AD pathologies.
Previously published studies conflict on the relation-
ship between CAA and cortical microinfarcts. CAA was
found to be associated with microinfarcts in the allocor-
tical region in an unselected, but not population-
representative, autopsy series [15] and CAA correlated
with microinfarcts in a small series of vascular dementia
cases [14]. In HAAS, CAA was not associated with is-
chaemic or haemorrhagic lesions [35]. Previous work in
CFAS did not find a relationship between CAA and
microinfarcts [16], but CAA assessment in that study
was based on a version of CERAD assessment of the
case prior to systematic adoption of CAA into the
CERAD protocol. Using a more rigorous assessment, we
confirm that microinfarcts do not show a statistical
relationship to CAA in this cohort. We did not confirm
the specific association found in occipital cortex [20], al-
though this could be an effect of small numbers with
microinfarcts in each cortical area. Further data on the
relationship of CAA to specific forms of vascular brain
pathology are required to resolve these inconsistencies.
CAA is associated with dementia, mild cognitive impair-
ment and more focal measures of impaired cognition such
as perceptual speed and episodic memory [2, 5, 9, 15].
These effects may be separate from the effects of AD
neuropathological change. In HAAS, CAA did not alter
the risk for dementia, but there was a significant inter-
action between CAA and AD neuropathological change
so that cognition in men with both was worse than in
those with either alone [35]. Univariate analysis in the
present study showed that the number of areas involved
by CAA was a predictor of dementia of similar magnitude
to parenchymal Aβ scores, but in multivariable modelling
it contributed little additional predictive information.
Binary cognitive stratification in our study was limited to
dementia status and we cannot exclude a contribution of
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CAA to mild cognitive impairment or more specific cog-
nitive domains.
PART
Within the continuum of Aβ and tau pathology we de-
fined cases with neurofibrillary tangles (up to Braak
stage IV) but with absent or low level Aβ deposition that
correspond to the definition of PART [10]. We also
defined a comparison group, PART-c, with a higher
burden of Aβ-pathology (as may be expected from cases
more typically on an AD pathological trajectory). PART-
d cases (those with Thal phase 0) were present at a
frequency of about 10% in our population sample.
Whether PART falls within the AD spectrum or is a
distinct age-related tauopathy is unresolved [11]. Be-
cause Aβ and NFT burden across the population lie on
continuums, PART may not be patho-aetiologically
distinct but merely represent cases lying off the main
sequence of AD neuropathology progression (Fig. 5). In
this study there is no evidence to define this pathological
constellation as a distinct disease group. It is also
possible to select a group with Aβ pathology but with no
or minimal tangle formation who also demonstrate a
spectrum of clinical outcomes.
Defining entities like PART, with varied relative bur-
dens of the different AD neuropathological lesions is im-
portant to appreciate the heterogeneity, and possible
implications, of late-life AD neuropathologic change.
Low parenchymal Aβ in PART is not due to preferential
distribution into vessels since CAA was higher in the
PART-c group. Rather, the higher CAA in low-Braak
stage cases with parenchymal amyloid reflects a correl-
ation between parenchymal Aβ and CAA. It has been
suggested that, as an age-related tauopathy, PART might
be associated with more severe mesial temporal tau [11].
The present data do not demonstrate a higher hippo-
campal tau stage [23] in PART, and PART cases were
not older than PART controls. We did find an associ-
ation between PART and thorn-shaped astrocytes, which
are a feature of age-related tau astrogliopathy (ARTAG)
[18, 45], so that ageing mechanisms likely influence
PART pathogenesis.
Conclusions
More detailed approaches to staging are helpful to ap-
preciate and stratify heterogeneity within the spectrum
of late-life AD neuropathological change. Ultimately
such stratification is only useful if it can contribute to
enhanced understanding of dementia risk and pathogen-
etic cascades. More granular characterisation is poten-
tially important to assess the impact of brain ageing and
genetic factors on pathological heterogeneity and cogni-
tive outcomes. The incorporation of advanced bioinfor-
matics approaches in this study shows that combining
Thal phase, CERAD score and improved semi-quantitative
assessment of CAA, assessing different aspects of Aβ path-
ology, does not improve dementia prediction, possibly be-
cause such variables are correlated. Selection of specific
amyloid assessment protocols for diagnostic and research
purposes clearly requires careful consideration but is not
likely to generate significantly conflicting estimates of diag-
nostic categories between studies.
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